Methaemoglobinaemia secondary to topical lignocaine/ prilocaine in a circumcised neonate

J Paediatr Child Health. 2000 Aug;36(4):406-7. doi: 10.1046/j.1440-1754.2000.00508.x.

Abstract

The use of topical lignocaine/prilocaine (EMLA, Astra Pharmaceuticals, North Ryde, NSW, Australia) for pain relief for neonatal circumcision is becoming more prevalent. Because of immaturity of the methaemoglobin reductase pathway, the neonate is vulnerable to methaemoglobinaemia which is a recognized complication of prilocaine therapy. This is the second report of methaemoglobinaemia due to the use of EMLA in association with circumcision during the newborn period.

Publication types

  • Case Reports

MeSH terms

  • Anesthetics, Combined / adverse effects*
  • Anesthetics, Local / adverse effects*
  • Circumcision, Male*
  • Humans
  • Infant, Newborn
  • Lidocaine / adverse effects*
  • Lidocaine, Prilocaine Drug Combination
  • Male
  • Methemoglobinemia / chemically induced*
  • Prilocaine / adverse effects*

Substances

  • Anesthetics, Combined
  • Anesthetics, Local
  • Lidocaine, Prilocaine Drug Combination
  • Prilocaine
  • Lidocaine